Mabwell (Shanghai) Bioscience Co. Ltd. A
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of p… Read more
Mabwell (Shanghai) Bioscience Co. Ltd. A (688062) - Total Liabilities
Latest total liabilities as of September 2025: CN¥3.58 Billion CNY
Based on the latest financial reports, Mabwell (Shanghai) Bioscience Co. Ltd. A (688062) has total liabilities worth CN¥3.58 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Mabwell (Shanghai) Bioscience Co. Ltd. A - Total Liabilities Trend (2017–2024)
This chart illustrates how Mabwell (Shanghai) Bioscience Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Mabwell (Shanghai) Bioscience Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Mabwell (Shanghai) Bioscience Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Seria Co. Ltd
PINK:SAOGF
|
USA | $32.66 Billion |
|
Inmyshow Digital Technology Group Co Ltd
SHG:600556
|
China | CN¥1.41 Billion |
|
Luster LightTech Co. Ltd. Cl A
SHG:688400
|
China | CN¥2.05 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥404.22 Million |
|
Hanma Technology Group Co Ltd
SHG:600375
|
China | CN¥4.94 Billion |
|
Kent Gida Maddeleri Sanayi ve Ticaret AS
IS:KENT
|
Turkey | TL408.76 Million |
|
Home First Finance Company India Limited
NSE:HOMEFIRST
|
India | ₹100.87 Billion |
|
TripAdvisor Inc
NASDAQ:TRIP
|
USA | $1.98 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Mabwell (Shanghai) Bioscience Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.71 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.79 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mabwell (Shanghai) Bioscience Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mabwell (Shanghai) Bioscience Co. Ltd. A (2017–2024)
The table below shows the annual total liabilities of Mabwell (Shanghai) Bioscience Co. Ltd. A from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.72 Billion | +44.53% |
| 2023-12-31 | CN¥1.88 Billion | +69.71% |
| 2022-12-31 | CN¥1.11 Billion | +89.02% |
| 2021-12-31 | CN¥586.65 Million | +248.27% |
| 2020-12-31 | CN¥168.45 Million | -46.50% |
| 2019-12-31 | CN¥314.87 Million | -69.24% |
| 2018-12-31 | CN¥1.02 Billion | +85.12% |
| 2017-12-31 | CN¥552.93 Million | -- |